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Prostate cancer (PCa) is the second most diagnosed cancer among males worldwide. Due to the current molecular 
markers used in clinic there is an overdiagnosis and patient overtreatment, revealing the need for biomarkers and 
gene signatures capable of stratifying patients, distinguishing aggressive prostate tumors from the indolent ones. 
Our laboratory has previously reported a master co-regulator of PCa metabolism capable of exerting a tumor and 
metastasis suppressive response: the peroxisome proliferator-activated receptor gamma co-activator 1 (PGC1α). 
PGC1α has been shown to prevent tumor growth, metastasis and invasion in PCa, associated with the 
downregulation of c-MYC. Given the unknown molecular mechanisms driving the biological effects of PGC1α and 
a recent RNA-sequencing experiment carried out in our laboratory, we hypothesize that the interferon transcriptional 
program upregulated by PGC1α drives its tumor suppressive activity. Interferons (IFNs) are cytokines greatly 
studied in cancer due to their ability to directly and/or indirectly modulate tumorigenesis. However, their role on 
PCa is not completely studied. In this context, we have characterized the PGC1α-driven phosphorylation of STAT1 
and the subsequent upregulation of the IFN transcriptional program in (i) PGC1α expressing and (ii) IFN-β treated 
PCa cells. Lastly, in co-cultures assays, we have approached the study of the anti-proliferative effect of the cell 
communication between PGC1α expressing and non-expressing PCa cells. Altogether, we consider the present work 
a first approach to studying the link between IFN pathway and the tumor suppressive properties of PGC1α in PCa 
cells, offering potential for new therapeutic targets and strategies. 
Image created using BioRender 
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1. Introduction 
Prostate cancer (PCa) is the second most frequent diagnosed cancer among males worldwide, with an estimated 
1,400,000 cases and 375,000 deaths in 2020. In developed countries, PCa shows the highest incidence among 
cancer types in men, representing the third cause of death by cancer in the gender1. Prostate-specific antigen 
(PSA) is the usual molecular marker used for the detection and monitoring of PCa. However, PSA screening 
has been highly controversial, due to the detection of inherently benign tumors and the fact that PSA levels 
can be influenced by other physiological factors. This results in an overdiagnosis and patient overtreatment, 
which questions the effectiveness of this biomarker by itself as an early detection tool2. 
PCa treatment ranges from active surveillance to a combination of surgery, radiotherapy, chemotherapy and/or 
androgen deprivation therapy (ADT). Low-risk cancers are usually handled by active surveillance, while high-
risk cancers (primary tumors) are managed with a more aggressive treatment, including surgery and 
radiotherapy. The major challenge comes to intermediate-risk tumors, due to the inability to differentiate 
between aggressive and non-aggressive cancers. A key feature of PCa is hormone responsiveness and the 
standard care for advanced PCa is ADT2,3. ADT can be approached by surgical castration, or more commonly, 
by chemical castration, with drugs targeting androgen receptor signaling. Although the majority of the patients 
respond well to ADT, resistance can develop, resulting in castration-resistant PCa. Considering that metastatic 
disease is the leading cause of death in PCa, research is focusing on the development of more accurate detection 
techniques and biomarkers that can effectively distinguish between aggressive and indolent forms of PCa in 
the earliest stages of the disease3. 
It is well accepted that the uncontrolled growth of tumors is not only supported by a deregulation of the cell 
proliferation mechanisms, but also by reprogramming the energy metabolism, an emerging hallmark of 
cancer4. Integrating computational biology, murine models and high throughput OMICs, our laboratory group 
has formerly reported that the peroxisome proliferator-activated receptor gamma co-activator 1 alpha 
(PGC1α), a master co-regulator of PCa metabolism, is central for the progression of the disease5. PGC1α is 
preferentially expressed in tissues with high oxidative capacities (such as skeletal muscle or brown adipose 
tissue) and interacts with a variety of transcription factors (TFs), serving as a pleiotropic regulator of the cell 
metabolism. The N-terminal of PGC1α contains several leucine-rich motifs (LXXLL), crucial for the 
interaction with the different TFs6. Some of these TFs include the estrogen-related receptor alpha (ERRα), 
retinoid receptors, nuclear respiratory factor-1 and -2 (NRF-1, NRF-2) or peroxisome proliferator-activated 
receptors (PPARα, PPARβ, PPARγ)7. PGC1α partnering with these TFs carries out its main biological 
functions: mitochondrial biogenesis, fatty acid oxidation and muscle fiber regeneration. The expression and 
activity of PGC1α is controlled by physiological and environmental stimuli, modulating the energy 
metabolism of the cell6, 7. Therefore, it comes as no surprise the implication of this co-regulator in cancer, since 
tumor cells continuously adapt their metabolism in response to their microenvironment.  
The role of PGC1α is tumor type and context-specific and can be discordant in different scenarios. In breast 
cancer, metastatic cells rely on PGC1α for metastatic dissemination, enhancing oxidative phosphorylation8. 
Moreover, PGC1α is overexpressed in breast cancer cells that metastasize to lung and bone9. Nonetheless, the 
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expression of PGC1α exerts an anti-proliferative effect in PCa, preventing tumor growth and metastatic 
dissemination5, 10.  
The loss of the expression of PGC1α in prostate cancer is associated with a metabolic rewiring, towards the 
activation of anabolism at the expense of a reduction in the catabolism. At the transcriptional level, the decrease 
in PGC1α expression defines a gene signature that is progressively downregulated in PCa primary tumors and 
metastasis, presenting prognostic potential for the stratification of patients5.  
The role of the oncogenic protein c-MYC has been widely studied in human tumors. Enhanced MYC 
expression has been shown to reprogram cellular metabolism, sustaining a high rate of proliferation in cancer 
cells11. In PCa murine models, the expression of human MYC has been shown to be an initiating event in the 
development of murine prostate tumors, highlighting the importance of this TF in the disease12. Furthermore, 
a recent study from our laboratory has demonstrated that the expression of PGC1α decreases invasive 
capacities in PCa cells through cytoskeletal remodeling, together with the inhibition of integrin β1, β4 and c-
MYC10. However, the exact molecular mechanisms driving the biological effects of PGC1α are still unknown. 
Interferons (IFNs) are pleiotropic cytokines that serve as a defense mechanism against viral infections13,14. 
Nonetheless, IFNs have been extensively studied in cancer, due to their ability to regulate tumorigenesis in a 
direct or indirect way. IFN type I molecules (IFN-α and IFN-β) signal through the IFNAR1-IFNAR2 receptor 
dimer. After the ligand has bound, the receptor-associated kinases JAK1 and TYK2 are phosphorylated. These 
phosphorylated kinases serve as a docking and activation platform for the recruitment and downstream 
phosphorylation of STAT proteins. The canonical signaling complex for IFN type I signaling is a STAT1-
STAT2-IRF9 complex (ISGF3 complex), which migrates to the nucleus and promotes the transcription of IFN-
response genes13. Deciphering the role of IFNs in PCa is important owing to their tumor suppressive properties. 
Previous studies have shown that IFN type I cytokines upregulate the inhibitor of cell cycle progression p2115 
and exert an invasion-suppressor activity in PCa cells16. Furthermore, PCa cells engineered to produce IFN-β 
have shown to suppress angiogenesis, growth and metastasis in mouse models in vivo17.  
In this context, a recent RNA Sequencing (RNA-Seq) experiment carried out in our laboratory revealed an 
upregulation of the IFN signaling transcriptional program in response to PGC1α re-expression in PCa cells. In 
line, previous data from the lab have shown an increase of IFN-β in the secretome of PGC1α expressing PCa 
cells and that this secretome has an anti-proliferative effect. Therefore, in this work we aim to further elucidate 
the role of these cytokines and their associated signaling pathway in PCa cells. 
2. Hypothesis and Objectives 
Taking into account the preliminary data of the lab and given the unknown molecular mechanisms driving the 
biological effects of PGC1α, we hypothesize that this IFN transcriptional program drives PGC1α’s tumor 
suppressive activity that ultimately could be transmitted in a paracrine manner to adjacent cancer cells. 
Therefore, in this work we ambitioned to: (i) characterize the PGC1α-driven IFN pathway in PCa cells,                   
(ii) confirm the tumor suppressive activity of IFN signaling in PCa cells, and (iii) approach the extrinsic tumor 
suppressive activity of PGC1α	in co-culture assays. 
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3. Materials and Methods 
3.1. Cell lines and culture conditions: 
Prostate cancer cell line PC3 was used in this work. These cells are epithelial cells derived from a bone 
metastasis of a grade IV prostatic adenocarcinoma from a Caucasian 62-year-old male. Previously in the lab, 
this cell line was modified to stably express the mouse Pgc1a gene with a doxycycline-inducible lentiviral 
vector (TRIPZ vector). This cell line, PC3 TRIPZ-HA-Pgc1a (from now on referred as PC3 PGC1α), in the 
presence of doxycycline in the medium overexpresses PGC1α. As control, PC3 cells transduced with TRIPZ 
empty vector (without the Pgc1a construct) were also used, PC3 TRIPZ. In the c-MYC exploratory 
experiments a third line was used, PC3 pLKO TetOn shMYC (PC3 shMYC), a modified PC3 cell line that in 
the presence of doxycycline expresses a validated shRNA against human MYC18. For the co-culture 
experiments a fourth cell line was used, PC3 TRIPZ-mCherry (PC3 mCherry), a modified PC3 cell line 
transduced with a TRIPZ vector containing the mCherry sequence, constitutively expressing the fluorescent 
protein mCherry.  
All cell lines were cultured using Dulbecco’s Modified Eagle Medium (1x) (DMEM) supplied with 10% 
inactivated Fetal Bovine Serum (FBS) (Gibco) and 1% Penicillin/Streptomycin (Gibco). Cell lines were grown 
at 37ºC in a humidified atmosphere of 5% CO2. Cells were regularly cultured in 100mm dishes and split every 
3-4 days, maintaining them below 80-90% density. For splitting and seeding, 0.25% trypsin-EDTA (1x) 
(Gibco) diluted 1:4 in Dulbecco’s Phosphate Saline Buffer (1x) (DPBS) was used. For splitting or cell 
counting, cells were detached from the plates by incubating with the trypsin-EDTA solution for 4 minutes at 
37ºC. Fresh DMEM was added for inactivation of the trypsin.  
For cell counting, the resuspended cells were diluted 1:2 in Trypan Blue Dye 0.4% and 10 µL were loaded in 
the Neubauer chamber. The viable cells (not stained with the dye) were counted by optical microscopy. Cell 
counting was performed at least twice for each sample to obtain a more accurate count. 
Co-cultures: For co-culture experiments different cell mixtures were prepared as represented in Table 1. The 
growth rate of each independent cell line was also measured.  
Table 1. The three different co-culture conditions prepared for the growth curve and flow cytometry assays. 
Co-culture condition PC3 mCherry (%) PC3 PGC1α or PC3 TRIPZ (%) 
80:20 80 % 20 % 
50:50 50 % 50 % 
20:80 20 % 80 % 
 
Doxycycline (Dox) was used at a final concentration of 0.5 µg/ml (Sigma #D9891). For the interferon 
experiments 3 different concentrations of human recombinant IFN-β (hIFN-β1a, Miltenyi Biotech) were used: 
25, 125 and 250 pM. All the experiments were performed after 3 days of pre-induction with Dox of the cells, 
with the exception of interferon experiments and time-course experiments. The composition of the buffers 
used is presented in Supplementary Table 1. 
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3.2. Cellular experiments: 
Cell growth analysis 
To monitor cell growth, 10K cells/well were seeded in triplicate in 12-well plates for days 0 (seeding control), 
3 and 6. In the interferon experiments, the day after seeding the medium was replaced with fresh medium with 
the different IFN-β concentrations. For fixation each well was washed with DPBS (1x) and 1 mL/well of 
formalin (10%) was added to the plates and stored at 4ºC until the end of experiment (day 6). For cell number 
quantification, formalin was discarded and cells were stained with crystal violet (0.1% in 20% methanol) for 
45 minutes. After rinsing with water and air drying the plates, the precipitate was solubilized in 10% acetic 
acid. Resolubilized crystal violet was transferred to a 96 well-plate and absorbance was measured at 570 nm 
using the PowerWave XS Microplate Spectrophotometer (BioTek). The absorbance measured at days 3 and 6 
was normalized by the absorbance at day 0, obtaining the growth fold-change relative to day 0. 
Flow cytometry assays 
In order to follow up the different cell percentages (%) in the co-culture conditions, 40K cells/well were seeded 
in duplicate in 6-well plates for days 0 (seeding control), 3, 6 and 9. On days 0, 3, 6 or 9, after medium was 
discarded, cells were washed with DPBS (1x), 250 µL of trypsin were added to each well and plates were 
incubated at 37ºC for 4 minutes. Cells were then resuspended with 1 mL DPBS (1x) and transferred to a 
separate Falcon 15 mL tube. Tubes were centrifuged (1500 rpm, 3 min, 4ºC) and the supernatant was discarded. 
Cell pellets were resuspended in 1 mL of DPBS (1x) and the centrifugation was repeated under the same 
conditions. The supernatants were removed, the cells were resuspended with 500 µL of DPBS (1x) and 
transferred to a flow cytometer tube that were kept on ice.  
Selection of the cell population of interest was done using the representation of the forward scattered light 
(FSC) vs. side scattered light (SSC). FSC intensity is proportional to the cell size, while SSC provides 
information about the internal complexity of cells. The cytometer data was analyzed using the Flowing (Turku 
Bioscience) software. The constitutively expressed mCherry protein in PC3 mCherry cells allowed to divide 
the cell population into two different subgroups attending to the emitted fluorescence. The % of each subgroup 
was calculated as the counts of cells in that subgroup divided by the total counts of the cell population.  
3.3. Molecular experiments: 
Gene expression analysis 
Between 75-100K cells/well were seeded in duplicate in 6-well plates and cells were collected after the 
indicated time points. Before RNA extraction, plates/wells were washes with DPBS (1x), snap-frozen in liquid 
N2 and stored at -80ºC. Once all experiments were collected, RNA was extracted using the NucleoSpin RNA 
isolation kit from Macherey-Nagel (ref: 740955.240C). Final RNA concentration was measured in a Biodrop 
spectrophotometer and samples were stored at -20ºC. For cDNA synthesis 1 µg of total RNA was 
retrotranscribed. The mix of retrotranscription contained RNA (1	µg), the enzyme Thermo Scientific Maxima 
H Minus cDNA synthesis Master mix (5x) and RNase free water (up to final volume, 10 µL). The samples 
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were placed in a thermocycler and the following program was used: 10 minutes at 25ºC, 15 minutes at 50ºC 
and lastly 5 minutes at 85ºC. The resultant cDNA was diluted 1:10 in distilled water and kept at -20ºC.  
Quantitative real-time PCR (qPCR) was performed in a QuantStudio 5 Real-Time PCR Instrument (384-Well 
Block) (Applied Biosystems). The program used for amplification was the following: 2 minutes at 50ºC and 
10 minutes at 95ºC, followed by 40 cycles of 15 seconds at 95ºC and 1 minute at 60ºC. Quantification was 
carried out using TaqMan probes (Applied Biosystems) or SYBR Green (Roche).  
TaqMan probes are specifically designed for the candidate gene and consist of a reporter and a quencher (which 
are attached to the 5’ and 3’ end of the probe, respectively). When these are released by the 5’-3’ exonuclease 
activity of the DNA polymerase, the reporter’s fluorescence is detected. SYBR Green is an intercalating dye 
that has a high binding affinity for double strand DNA (dsDNA). Once the dye binds to dsDNA its fluorescence 
increases and can be measured in the extension phase of each cycle. Given the nonspecificity of this last 
quantification method, a melting curve analysis is highly recommended. In both cases, the emitted fluorescence 
follows a sigmoidal increase and the threshold cycle (Ct) is used to calculate the initial DNA copy number19.  
For the TaqMan reaction, 3 µL of the diluted cDNA were mixed with 3 µL of the TaqMan Universal Master 
Mix II, with UNG (2x, Applied Biosystems), left and right primers at a final concentration of 200 nM and 
TaqMan probes at a concentration of 100 nM. For the SYBR Green reaction, 3 µL of the diluted cDNA were 
mixed with 3 µL of the FastStart Universal SYBR® Green Master (Roche) and left and right primers at a final 
concentration of 200 nM. All qPCR data presented were normalized using GAPDH (housekeeping gene) levels 
as reference. The primers used are presented in the Supplementary Table 2. 
Protein analysis 
Between 75-100K cells/well were seeded in duplicate in 6-well plates and cells were collected after the 
indicated time points. Before protein extraction, plates/wells were washes with DPBS (1x), snap-frozen in 
liquid N2 and stored at -80ºC. Once all experiments were collected, cells were lysed using 75 µL/well of RIPA 
buffer. Lysates were transferred to Eppendorf tubes, kept for 20 minutes on ice and vortexed every 5 minutes. 
Samples were then centrifuged (15 000 g, 15 min, 4ºC) and the supernatant was collected. Protein 
quantification was carried out using PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific, 23225). A 
calibration curve was prepared using different concentration of Bovine Serum Albumin (BSA, 0.5-8 mg/mL) 
and 1 µL of the protein samples was mixed with 9 µL of milli-Q water. In a 96-well plate BSA and protein 
samples were loaded in duplicate. 200  µL/well of the BCA Reagent was added and the plate was incubated at 
37ºC for 30 minutes. Absorbance was measured at 562 nm using the PowerWave XS Microplate 
Spectrophotometer (BioTek). The same protein concentration was achieved in all samples adding milli-Q 
water and Laemmli Loading buffer 5x. 
Protein lysates with Laemmli buffer 1x were boiled at 96ºC for 5 minutes for protein denaturation. The boiled 
samples were subjected to SDS-PAGE. The proteins were resolved either in homemade acrylamide gels or in 
CriterionTM XT Precast gels (4-12% acrylamide, 12+2 well comb). Homemade gels (stacking 5% and resolving 
10% acrylamide) were prepared as described in Table 2. 
 7 
Table 2. Recipes used for preparing homemade acrylamide gels. 
 Running gel (10%) Stacking gel (5%) 
30% Acrylamide 10 % 5 % 
Tris (1.5 M, pH=8.8) 25 % 25 % 
10% SDS 1 % 1 % 
10% APS 1 % 1 % 
TEMED 0.04 % 0.04 % 
Milli-Q water Up to final volume Up to final volume 
 
In the case of homemade gels, the proteins were stacked at 90V for 15 minutes and resolved at 150V for 1 
hour and 15 minutes in Tris/Glycine buffer. In the case of precast gels, proteins were resolved at 180V for 1 
hour and 30 minutes in MOPS buffer. Pink pre-stained protein marker (Nippon MWP02, DDBiolab) was used 
as a protein weight marker. Then, proteins were transferred to nitrocellulose membranes at 100V during 1 hour 
(for homemade gels) or 80V during 1 hour and 30 minutes (precast gels) in transfer buffer. Membranes were 
blocked with 5% non-fat milk prepared in Tris-buffered saline solution containing 0.01% Tween-20 (TBST) 
for 1 hour. 
Primary antibodies were prepared in TBST with 0.002% sodium azide and incubated with the membranes 
overnight at 4ºC. All antibodies were used at a 1:1000 dilution, except β-Actin (1:2000). Membranes were 
then washed 3 times (10 minutes each) with TBST and were incubated with the secondary antibody diluted 
1:4000 in 5% non-fat milk for 1 hour at room temperature. After that, membranes were washed again 3 times 
with TBST and developed with ClarityTM Western ECL Substrate (Bio-Rad). Proteins were visualized using 
the Chemidoc Imaging system. The antibodies used are presented in Supplementary Table 3. 
3.4. Statistical analysis: 
GraphPad Prism 8 software was used for statistical analysis. In all experiments the confidence level used was 
95% (α =0.05). n values represent the number of independent experiments performed. One sample t test was 
applied for one-component comparisons with control (hypothetical value=1). In co-culture experiments, for 
the comparison expected and measured values multiple t tests were applied. One-tail statistical analysis was 
applied for validation of predicted results (hypothesis-driven experiments) and two-tailed statistical analysis 
was applied for experiment design without predicted result. In the figures presented mean ± standard error of 
the mean (SEM) is presented. 
4. Results 
4.1. Characterization of the interferon response on PCa cell line: 
The RNA-Seq analysis previously carried out in our laboratory showed an upregulation of the interferon (IFN) 
signaling transcriptional program in response PGC1α re-expression (Fig. 1A). In order to validate these results, 
the expression of some IFN-response genes was analyzed 6 days after PGC1α induction (Fig. 1B).  For the 
benefit of having a comprehensive view, the data previously obtained in the lab were also included in the 
figure. Our results confirm the upregulation of the IFN signaling previously observed, reassuring that PGC1α 
is capable of driving an interferon transcriptional response. 
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Next, we wondered if this IFN signaling was mediating the anti-proliferative effect of PGC1α. But first, we 
aimed to proof the biological effect of IFN treatment on PC3 cells. In order to do so, PC3 cells were treated 
with three different concentrations of human recombinant IFN-β (25, 125 and 250 pM). The growth of IFN-β 
treated PC3 cells was measured at days 3 and 6. Our results show that IFN-β has a significant anti-proliferative 
effect in a doses-dependent manner (Fig. 2A). Furthermore, the morphology of the cells was also evaluated in 
response to the drug treatment. Membrane prolongations appeared and stress granules became more apparent 
after 3 days of treatment (Fig. 2B). With these results we confirm the anti-proliferative effect of IFN-β on PC3 
cells and further supports our hypothesis that this could be one of the pathways through which PGC1α 
modulates cell proliferation. 
Once characterized the anti-proliferative effect, we asked if in addition to proliferation, IFN-β treatment could 
phenocopy PGC1α-induced transcriptional program. For gene expression analysis we used the intermediate 
concentration of IFN-β, 125 pM. We evaluated the gene expression changes induced by IFN-β at 8, 24 and 
72h of treatment in PC3 cells (Fig. 2C). IFN-β treatment upregulated the expression of IFN-response genes at 
early time-points (8 and 24h) and these transcriptional changes were not maintained over time (72h) (Fig. S1). 
The genes upregulated in the RNA-Seq analysis were also upregulated in treated cells, showing that IFN-β 
activates the same transcriptional program induced by PGC1α. Out of all the IFN-response genes analyzed, 
some of them were not upregulated, suggesting that the doses used were not enough for their overexpression 
or they are not responsive to IFN-β, but to other IFN type I cytokines. However, some genes such as MX1, 
ISG15 or OAS1 showed an early (8h) and significant upregulation in response to IFN-β, pointing out that these 
genes could be the earliest reporters of an IFN signaling activation in PC3 cells out of all of the IFN-response 
genes analyzed.   
 
Figure 1. PGC1α upregulates the IFN 
signaling transcriptional program in vitro 
in PC3 cells. (A) RNA-Seq enrichment 
analysis of the transcriptional program 
upregulated by PGC1α. (B) qRT-PCR 
gene expression analysis of IFN-
response genes and PGC1α after a 6 day 
Dox treatment (n=3). Data are 
represented as fold-change relative to -
Dox cells, depicted as a dotted line. The 
data represented in white dots were 
obtained previously in the lab.                                               






4.2. Tracking the PGC1𝛂-driven molecular events over time: 
The phosphorylation and further dimerization of STAT1 and STAT2 leads to the formation of the ISGF3 
complex (together with IRF9), which migrates to the nucleus and activates the IFN response transcriptional 
program13. Therefore, we sought to interrogate whether the expression of PGC1α could trigger the 
phosphorylation of STAT1, and the subsequent activation of the IFN signaling program. In order to do so, 
phospho-STAT1 (P-STAT1) was analyzed 6 days after Dox treatment on PC3 PGC1α cells (Fig. 3A). Our 
results show a significative increase in P-STAT1 protein level, suggesting that PGC1α promotes the 
phosphorylation of STAT1. Aiming to track the different molecular events over time, a Dox treatment time-
course (16, 24 and 48h) was performed (Fig. 3B, C). 
Our results confirm the decrease in c-MYC protein level previously characterized10 and show an increase in 
P-STAT1 protein level at 16h after PGC1α overexpression, that is maintained at 24h and 48h. Although these 
results indicate that the phosphorylation of STAT1 occurs early in time, it is preceded by the downregulation 
of c-MYC, which occurs at a transcriptional level only 2h after PGC1α expression.  In order to study if this 
early activation of IFN pathway was accompanied by an activation of a transcriptional response, four IFN-
response genes were selected: STAT1, IRF1, MX1 and ISG15; these last two being considered early target 
genes as our previous results suggested. Although at 16 and 24h there was an uncertain MX1 upregulation, at 
48h this overexpression became significant. These data, together with the upregulation observed at 6 days after 
the expression of PGC1α, suggest that PGC1α is capable of driving an IFN response signaling mediated by 
the phosphorylation of STAT1, starting to activate this transcriptional program 48h after its re-expression.  
Figure 2. IFN-β modulates cell proliferation and activates IFN signaling transcriptional program in PC3 cells in vitro. 
(A) Effect of IFN-β (25, 125 and 250 pM) on the growth rate of PC3 cells at 3 and 6 days post-treatment relative to 
untreated cells (n=3). (B) Optical microscopy photographs representative of the changes in cell morphology 3 days after 
treatment. Bar scale: 100 μm. (C) qRT-PCR gene expression analysis of IFN-response genes at 8 and 24h after an IFN-
β treatment (125 pM) (n=3). Data are represented as fold-change relative to untreated cells, depicted as a dotted line. *: 







4.3. Studying the connection between c-MYC and IFN pathway driven by PGC1𝛂: 
The decrease in c-MYC driven by PGC1α has previously been demonstrated to have tumor suppressive activity 
and the silencing of this transcription factor partly phenocopies the effect of PGC1α10. Once we demonstrated 
an upregulation of the IFN pathway driven by PGC1α, we wondered if the decrease in c-MYC (see Fig. 3B) 
could be mediating these transcriptional changes. In order to explore this possible connection, we studied the 
expression of three IFN-response genes in PC3 shMYC cells (Fig. 4). Our results showed an increase in the 
expression of these genes in response to the downregulation of MYC, although not statistically significant. 
These changes in the gene expression support the hypothesis that a PGC1α-driven downregulation of c-MYC 
positively modulates the IFN transcriptional program, as a part of its tumor suppressive activity. However, the 















Figure 4. Silencing the transcription factor c-MYC 
upregulates an IFN signaling response 6 days after its 
downregulation in PC3 cells. qRT-PCR gene expression 
analysis of three IFN-response genes: MX1, ISG15 and 
OAS1 (n=3). Data are represented as fold-change relative to 
-Dox, depicted as a dotted line. *: p-value < 0.05. 
Figure 3. PGC1α activates IFN signaling response 48h after its re-expression in PC3 cells. (A) Representative Western 
blot analysis and quantification of the effect of PGC1α on STAT1 phosphorylation 6 days after its re-expression (n=3). 
(B) Representative Western blot analysis and quantification of the effect of PGC1α on STAT1 phosphorylation and               
c-MYC 16, 24 and 48h after its re-expression (n=3). (C) qRT-PCR gene expression analysis of IFN-response genes IRF1, 
STAT1, MX1 and ISG15 16, 24 and 48h after PGC1α induction (n=3). Data are represented as fold-change relative to               
-Dox, depicted as a dotted line. *: p-value < 0.05, **: p-value < 0.01. 
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4.4. Exploring the extrinsic biological effects of PGC1𝛂: 
Previous studies of our laboratory showed an anti-proliferative activity associated with the secretome produced 
by PGC1α expressing PC3 cells. Additional studies also demonstrated an increase of IFN-β in this secretome. 
In these experimental settings, secretome producer cells and recipient cells were never in contact. This idea 
led us to ask if this growth inhibitory response could be transmitted in a paracrine manner in a context closer 
to the physiological one. In order to further decipher the communication between aggressive (PGC1α-) and 
non-aggressive (PGC1α+) PCa cells, co-culture experiments were designed. PC3 mCherry was chosen as the 
aggressive cell line and PC3 PGC1α was chosen as the non-aggressive cell line. PC3 TRIPZ cells were used 
as a control, with the aim of ensuring that the outcome of the experiments could not be attributed to doxycycline 
treatment and/or the fact of mixing and culturing two different cell lines.  
Three different percentages of co-culture conditions (PC3 mCherry:PC3 PGC1α cells or PC3 TRIPZ cells) 
were studied (80:20, 50:50 and 20:80). Growth rates at days 3 and 6 were calculated as relative to day 0 for 
each condition (Fig. 5). In this first assay the overall growth of each co-culture condition was measured. The 
growth rate of each cell line was also determined in monocultures. Taking into account the growth rate of each 
cell line (monocultures) and the composition of each co-culture condition, expected growth rates were 
calculated for days 3 and 6. These expected growth rates represent the overall proliferation of each co-culture 
condition if cells grew independently, without any communication that could alter their proliferation. As 
anticipated, the overall growth rate decreases as the proportion of PC3 PGC1α cells increases, due to the slower 
growth rate of PC3 PGC1α cells (~3.5 times lower than PC3 mCherry cells at Day 6; not shown). In the case 
of PC3 TRIPZ co-cultures, the growth rate seems to be identical (n.s.) independent of the condition of study. 
The measured (real) growth rates were compared to the expected (calculated) ones. Results show no difference 
between the expected proliferation and the one measured in any of the different conditions. Therefore, these 
data suggest that the cell growth measured and the one expected if PC3 PGC1α  (PGC1α+) and PC3 mCherry 






Figure 5. Growth rate (fold-change) relative to Day 0 in different co-culture conditions. Growth evolution is shown for 
(A) the different co-cultures of PC3 mCherry and PC3 PGC1α cells and (B) the different co-cultures of PC3 mCherry 
and PC3 TRIPZ cells (n=4). Black dotted lines represent the expected growth rate for each co-culture condition, 
calculated from the growth rate of each cell line in monocultures. D0: Day 0; D3: Day 3; D6: Day 6.  
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Once studied the overall proliferation of the co-cultures, we were interested in following the percentage (%) 
of each cell population (PC3 mCherry and PC3 PGC1α) at the same time points previously studied (days 3 
and 6) and at day 9 as an exploratory approach (n=1). As did before, taking into account the growth rate of 
each cell line (monocultures) and the composition of each condition, the expected % of each population was 
calculated for days 3 and 6. These expected data were compared with the data obtained in the flow cytometry 
assays, representing the time evolution of the % PC3 mCherry cells in the time course of 9 days (Fig. 6A).  
The evolution of the % of PC3 mCherry cells in co-cultures reflects the growing tendency of this cell 
population. The growing behavior of these aggressive cells (and consequently of the non-aggressive ones) was 
different from the one expected. We distinguished two clear growing tendencies when compared the measured 
% PC3 mCherry and expected % PC3 mCherry cells (Fig. 6B). From D0 to D3, the percentage increase per 
day was significantly higher than expected; showing that during these first three days, the aggressive PCa cells 
proliferated more than expected if they grew in monoculture conditions. On the other hand, from D3 to D6, 
the percentage increase was significantly lower than the expected one; showing that during the following three 












Interferons, which are cytokines not only produced by tumor cells but also by the microenvironment, have 
shown to be capable of exerting a direct tumor-suppressive effect on tumor cells by modulating proliferation, 
differentiation, migration and antigen presentation13,14. In PCa the role of these cytokines has not been 
completely studied. A previous study on 118 PCa patients has reported that low-score values for IFN-β in 
prostate tumors were significantly associated with biochemical recurrence and worse prognosis14. Furthermore, 
a study of Shou and colleagues demonstrated that IFN pathway is indeed suppressed when benign PCa cells 
become tumorigenic15. Altogether these studies highlight the relevance of unravelling the role of these 
Figure 6. (A) Measured time evolution of the % PC3 mCherry cells through the course of 9 days. The measured % 
PC3 mCherry cells is shown in solid color lines for the three different co-culture conditions, while the expected % is 
shown in black dotted lines (n=3). The evolution of each condition from D6-D9 was studied without changing the 
medium (color lines) or discarding the medium and adding fresh one on days 3 and 6 (black solid lines); exploratory 
(n=1). (B) Increase in the % PC3 mCherry cells per day. The increase measured is shown in color bars and the expected 
one in black bars, for the two different time zones: D0–D3 and D3–D6. *: p-value < 0.05; **: p-value < 0.01; ***: p-
value < 0.001. D0: Day 0; D3: Day 3; D6: Day 6.   
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cytokines and their associated signaling pathway in prostate cancer, driven by the necessity of biomarkers and 
gene signatures capable of stratifying patients. 
In order to verify that IFN pathway activated by PGC1α drives its anti-proliferative effect, we first needed to 
assess the anti-proliferative effect of the cytokine itself in our cell system. When studied the IFN transcriptional 
program activated in response to IFN-β treatment, the upregulation was not the same for all the IFN-response 
genes analyzed. Three out of the nine canonical IFN type I genes studied were not upregulated (IRF1, IRF9 
and RNASEL). These data could be explained either because the concentration used was not enough for their 
overexpression or because they might not be responsive to IFN-β but to other IFN type I cytokines. 
Nevertheless, we consider the data obtained a good validation, demonstrating the link between IFN pathway 
and its growth inhibitory effect on PCa PC3 cells. Moreover, our results are in line with another study that has 
previously supported the tumor suppressive activity of IFN-β in PC3 cells at the same IFN-β doses tested16. 
Once studied the biological effect of IFN signaling and characterized the upregulation of IFN-response genes, 
both in treated cells and PGC1α-expressing cells, we aimed to track over time the molecular events triggered 
by the re-expression of PGC1α. The significant increase in P-STAT1 protein level 6 days after PGC1α 
induction was in line with our previous IFN-response genes expression data, which led us to propose that the 
IFN transcriptional program was driven by PGC1α possibly through the phosphorylation of STAT1, a novel 
molecular mechanism yet unknown. Nonetheless, in the results presented in Fig. 3A there is a decrease in total-
STAT1 in response to PGC1α expression. This result is inconsistent with the previously characterized 
upregulation of STAT1 at mRNA level. In previous Western blots carried out in our laboratory this result was 
not replicated. Therefore, we propose that this incoherence can be explained by a failed Western blot analysis. 
Although our results demonstrate a PGC1α-driven phosphorylation of STAT1 as early as at 16h, there was 
some uncertainty in the time-point at which an increase in P-STAT1 protein level occurs. Complementary to 
the time-course experiments presented, we performed a short time-course analyzing both gene and protein 
expression at 2, 4, 6 and 8h after PGC1α induction. The results were not conclusive, showing an increase in 
the phosphorylation of STAT1 at 8h in only two of the three experiments carried out. Together with the 
upregulation of MX1 at 48h after PGC1α re-expression, we propose this time-point as the beginning of the IFN 
transcriptional program observed at 6 days after PGC1α induction. 
Our data suggest that the PGC1α-driven STAT1 phosphorylation could trigger molecular events that induce 
the IFN transcriptional program and the subsequent growth inhibitory response observed. This molecular 
mechanism has not been previously reported in the literature, demonstrating the molecular complexity of the 
pathways modulated by the tumor-suppressor PGC1α in PCa. A previous study has uncovered a defective IFN-
JAK-STAT1 signaling pathway in PCa cells that was inactivated in a MYC-dependent manner20. Together, 
our preliminary data suggest that the tumor suppressive response of PGC1α is associated with the 
downregulation of c-MYC and the subsequent upregulation of the IFN pathway in PCa cells. A possible 
molecular mechanism for the activation of the IFN transcriptional program is a MYC-dependent activation of 
JAK or TYK kinases, mediating the phosphorylation of STAT1. 
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Through the co-culture experiments we aimed to study the biological effect of cell communication between 
PGC1α expressing and non-expressing PCa cells. The change in the growing tendency of PCa aggressive cells 
reflects an anti-proliferative response three days after seeding. According to previous studies of the lab and 
our last data, we hypothesize that during these first three days there is an upregulation of the characterized 
PGC1α-driven IFN pathway and a change in the secretome composition produced by PGC1α expressing cells. 
The accumulation of these secretome components in the culture medium during the first three days could be 
driving the growth inhibitory effect observed in aggressive cells in the following days. Moreover, striving to 
eliminate the secretome component, two different conditions were seeded and harvested on day 9. In the first 
one, the culture medium was replaced with fresh one every three days; while in the other one the medium was 
not changed. In the co-culture conditions where the medium was changed, a remarkable increase in the % of 
aggressive PCa cells was observed. Although additional experiments are required in order to provide consistent 
results, these preliminary results support our hypothesis, remarking the importance of the extrinsic effects of 
the re-expression of PGC1α. The pro-proliferative effect of PCa aggressive cells during the first three days 
was a novel and previously unexplored response. Additional controls using co-cultures of aggressive cells 
should be carried out. The pro-proliferative behavior of PCa aggressive cells in the first three days balances 
the anti-proliferative behavior of the next three days (see Fig. 6A at D6), explaining how there were no 
differences in the overall growth rate of the co-culture.  
Numerous studies have shown the ability of IFNs to modulate tumorigenesis in an paracrine manner exerting 
a tumor suppressive response and stimulating immune cytotoxic cells13,14. The extrinsic mechanisms of PGC1α 
contribute to its tumor suppressive activity and we hypothesize that IFN pathway can ultimately be transmitted 
in a paracrine manner, modulating the tumor microenvironment and opposing the progression of the disease.  
6. Future directions and Conclusions 
The molecular mechanism through which PGC1α promotes the phosphorylation of STAT1 and the activation 
of IFN transcriptional program is yet unknown. In order to explore this mechanism, it would be interesting to 
chemically inhibit the receptor associated kinases (JAK1 or TYK2) that drive the phosphorylation of STAT1 
or genetically silence IRF9, necessary for the formation of the ISGF3 complex. These experimental settings 
would allow us to better describe the role of PGC1α in the activation of this signaling pathway. In addition, 
we consider necessary to measure P-STAT2 protein level in response to PGC1α induction. Owing to the fact 
that some of the upregulated genes are exclusively modulated by IFN type I cytokines through the formation 
of the ISGF3 complex, we expect an increase in the phosphorylation of STAT2 driven by PGC1α. Studying 
the upregulated IFN type II (IFN-γ)-response genes would also be interesting, due to the plausible synergistic 
effects of IFN type I and II response genes involved in the tumor suppressive effect of PGC1α. 
The link between PGC1α-driven IFN pathway and the downregulation of c-MYC is an interesting novel 
mechanism that needs to be further studied. In order to statistically confirm the upregulation of IFN-response 
genes in response to MYC downregulation, a higher number of experiments is required. Although this approach 
is a good start, our hypothesis needs to be further supported by a downregulation of the IFN pathway in 
response to the rescue of MYC expression in PGC1α expressing PCa cells.  
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Related to the extrinsic mechanisms of PGC1α there are many aspects to shed light on. Although in this work 
we only characterized the biological effect of a paracrine communication between PGC1α expressing and non-
expressing PCa cells, we consider necessary to study the underlying molecular mechanisms. In order to do so, 
a Fluorescence-Activated Cell Sorting (FACS) experiment can be designed, in which aggressive (mCherry+) 
and non-aggressive cells could be separated. After doing so, we could study the IFN pathway with or without 
changing the culture medium in aggressive PCa cells at the different time-points analyzed.  
On the grounds of all these data, IFN-β and its associated signaling pathway are potent candidates for the 
development of antitumor drugs; however, recombinant IFN-β is too unstable to be used in therapy in vivo14. 
Moreover, clinical trials of immunotherapy for advanced PCa using IFN type I cytokines (IFN-α or IFN-β) 
have been shown not to be effective and in some cases, capable of inducing severe toxicity21. Therefore, new 
strategies need to be taken into account in order to present prognostic or clinical value. We consider the present 
work a first approach to studying the link between IFN pathway and the tumor-suppressive properties of 
PGC1α in PCa, offering potential for new therapeutic targets and strategies. 
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Supplementary T1. Composition of the buffers used. 
Buffer Composition 
RIPA buffer 
50 mM TrisHCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Nonidet 
P40, 1% sodium deoxycholate, 1 mM sodium fluoride, 1 mM sodium 




10% SDS, 50 mM Tris pH 6.8, 10% H2O, 50% glycerol, 1% β-mercaptoethanol, 
10 mM DTT and 0.2 mg/mL of bromophenol blue 
Transfer buffer 200 mM glycine, 25 mM Tris, 20% ethanol and milli-Q water up to volume 
 
Supplementary T2. Information about the primer sequences. 
Gene Species Left primer sequence Right primer sequence 
Pgc1a Mouse GAAAGGGCCAAACAGAGAGA GTAAATCACACGGCGCTCTT 
GADPH Human ACATCGCTCAGACACCATG TGTAGTTGAGGTCAATGAAGGG 
MX1 Human GAAAGAGGCGAAGCGAGAG CCGTGACACTGGGATTCCT 
ISG15 Human CGAACTCATCTTTGCCAGTACA GCCTTCAGCTCTGACACC 
OAS1 Human GTGAGCTCCTGGATTCTGCT AGGGTACTCATGTGTTCCAATGT 
STAT1 Human GAGCTTCACTCCCTTAGTTTTGA CACAACGGGCAGAGAGGT 
STAT2 Human TGCAGTTCCTCTGTCACACC GGTTTGATTTGGGACTTTGGT 
IFNB1 Human CTTTGCTATTTTCAGACAAGATTCA GCCAGGAGGTTCTCAACAAT 
IRF1 Human GGCACATCCCAGTGGAAG CCCTTCCTCATCCTCATCTGT 
IRF9 Human AGCCTGGACAGCAACTCAG GAAACTGCCCACTCTCCACT 
RNASEL Human AGCAGTCTTCCAGGCTTTG CAACAGAGCAGCAGTATGAAGA 
MYC Human TCCTCGGATTCTCTGCTCTC TCTTCCTCATCTTCTTGTTCCTC 
 
Supplementary T3. Information about the antibodies used. 
Protein Source Isotype Reference UniProt ID 
Molecular 
weight (kDa) 
STAT1 Cell Signaling Technology Rabbit IgG D1K9Y 
P42224 84-91 
P-STAT1 (Tyr701) Cell Signaling Technology Rabbit IgG 58D6 
c-MYC Cell Signaling Technology Rabbit IgG D3N8F P01106 57-65 
𝛃-Actin Cell Signaling Technology Mouse IgG 8H10D10 P60709 45 







Figure S1. qRT-PCR gene expression analysis of 
IFN-response genes at 72h after an IFN-β treatment 
125 pM (n=3; independent experiments). Data are 
represented as fold-change relative to untreated cells, 
depicted as a dotted line.  
